Mineralys Therapeutics, Inc. (Nasdaq: MLYS) is initiating a public offering of $175.0 million of its common stock.
The company plans to grant underwriters an option to purchase up to an additional $26.25 million of shares.
Proceeds from the offering will support clinical development of lorundrostat and other corporate activities.
Public Offering
Mineralys Therapeutics is offering $175.0 million of common stock, with an option for an additional $26.25 million at the public offering price.
Underwriters
BofA Securities, Evercore ISI, Goldman Sachs & Co. LLC, Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering.
Use of Proceeds
The net proceeds will fund clinical development of lorundrostat, research and pre-commercialization activities, working capital, and general corporate purposes.
- Mineralys Therapeutics aims to target hypertension and related comorbidities through the development of proprietary medicines.
- The public offering signals the company's strategic move to secure funding for ongoing research and development efforts.
The proposed public offering underscores Mineralys Therapeutics' commitment to advancing treatments for hypertension and related conditions, showcasing its dedication to research and development in the biopharmaceutical sector.